A Randomized, Multicenter, Phase III Trial of Trabectedin (Yondelis®) versus Doxorubicin-based Chemotherapy as First-Line Therapy in Patients with Translocation-Related Sarcomas (TRS)

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-002326-11

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate the efficacy of trabectedin vs. standard DXCT as first-line treatment of patients with advanced TRS, by comparing PFS in each treatment arm.


Critère d'inclusion

  • Translocation-Related Sarcomas